Browsing Tag
PYRUKYND
4 posts
Agios (AGIO) cuts R&D jobs as drug sales quadruple. Is its strategy changing?
Agios Pharmaceuticals expects to have eliminated more than 100 research and development roles by the end of 2026, reducing its R&D workforce by over 35%. The shift follows strong growth in mitapivat sales but comes as a key sickle cell disease regulatory decision moves to February 2027, creating a difficult balance between commercial expansion, research capacity and financial discipline.
Agios shakes up sickle cell therapy landscape with mixed but promising RISE UP phase 3 data for mitapivat
Find out how Agios’ mixed but promising RISE UP phase 3 data for mitapivat could reshape sickle cell treatment and influence regulatory decisions.
Agios Pharmaceuticals’ mitapivat meets primary endpoint in Phase 3 thalassemia trial
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), renowned for its innovative therapies in cellular metabolism and pyruvate kinase (PK) activation,…
Agios Pharmaceuticals gets PYRUKYND FDA approval for hemolytic anemia
Agios Pharmaceuticals has secured approval for PYRUKYND (mitapivat) from the US Food and Drug Administration (FDA) for the…